YY/T 1888-2023 in English
VALIDRecombinant humanized collagen protein
- Issued on:2023-01-18
- Implemented on:2023-07-20
- File Format:PDF
- Delivery:Via email within 1~3 business days
$272.00
本文件规定了重组人源化胶原蛋白的质量控制、技术要求、试验方法、稳定性、生物学评价以及包装、运输和贮存等。
本文件适用于作为医疗器械原材料的不含非人胶原蛋白氨基酸序列的重组人源化胶原蛋白的质量控制。
Introduction
Standard Background and Technology Evolution
YY/T 1888-2023 is my country's first industry standard for recombinant humanized collagen, marking the entry of genetic engineering collagen materials into the standardization stage of medical device applications. This standard is based on the general requirements of YY/T 1849-2022 "Recombinant Collagen" and makes special provisions for humanized characteristics.
Core quality control requirements
| Detection dimensions | Key indicators | Technical points |
|---|---|---|
| Physical and chemical properties | Purity ≥ 95% | SDS-PAGE and HPLC double verification |
| Structural characterization | Peptide coverage 100% | LC-MS multiple enzyme digestion verification |
| Impurity control | Host protein ≤ 0.05% | ELISA specific detection |
| Advanced structure | CD spectrum characteristic peaks | 195nm negative peak/221nm positive peak |
Key technological breakthroughs
1. Humanized sequence verification
It is required to provide a complete amino acid sequence comparison certificate, and use the NCBI database for human consistency verification to ensure that there are no non-human sequence fragments. Typical example: Human type III collagen (380G-641G) × 2 represents a repeating structure.
2. Structural characterization system
Establish a four-level detection system:
① Primary structure: mass spectrometry molecular weight (error ±1Da)
② Secondary structure: circular dichroism (CD)
③ Tertiary structure: differential scanning calorimetry (DSC)
④ Crystal structure: X-ray diffraction (resolution ≤3Å)
Implementation suggestions
Key points of production process control
- Expression system selection: Differences in residue control standards for E. coli/yeast/CHO cells
- Lyophilization process validation: Balance between moisture content and activity retention
- Additive management: Amount of cross-linking agent and residue detection method
Biological evaluation strategy
According to the requirements of GB/T 16886.1, special attention should be paid to the following:
• Immunogenicity assessment (GB/T 16886.20)
• Degradation characteristics of long-term implants
• Evaluation limitations caused by species differences
Industry impact analysis
The implementation of this standard will promote the standardized application of recombinant collagen in the following fields:
1. Wound dressings: microbial limit ≤100CFU/g
2. Cosmetic fillers: osmotic pressure 270-360mOsmol/kg
3. Tissue engineering scaffolds: bacterial endotoxin ≤5EU/kg

Loading PDF document...
Error loading PDF. Please make sure the file is valid and try again.
We also recommend
-

YY/T 1940-2024 in English
Medical Nitinol Powders for Additive Manufacturing
2024-09-29 -

YY/T 1764-2021 in English
Standard guide for in vitro axial,bending,and torsional durability testing of vascular stents
2021-09-06 -

YY/T 0993-2015 in English
Biological evaluation of medical devices―Nanomaterial:In vitro cytotoxicity tests(MTT assay and LDH assay)
2015-03-02 -

YY/T 1897-2023 in English
Biological evaluation of nanomedical devices Genotoxicity test In vitro mammalian cell micronucleus test
2023-06-20 -

YY/T 0149-2006 in English
Medical instruments of stainless steel - Test methods of corrosion resistance
2006-06-19 -

YY/T 1535-2024 in English
Human sperm survival test for medical devices used in human assisted reproductive technology
2024-07-08